Ductal adenocarcinoma of the pancreas (PDAC) accounts for more than 85% of PC and is an aggressive malignancy characterized by a high rate of distant metastasis and recurrence. Compared with other types of cancer, PC has a unique TEM that accounts for more than 80% of total pancreatic tumor masses, consisting of the extracellular matrix and numerous types of cellular components. Among them, cancer-associated fibroblasts (CAFs) are responsible for the production of extracellular matrix and regulation of tumor behavior, forming a physical barrier for drug delivery and leading to medication resistance.
Alfa Oncology is a leading custom service provider with experience in pancreatic cancer (PC) basic research. We are now proud to offer a full range of PC basic research services. Based on robust platforms, powerful analytics, cross-platform collaborations, and years of experience in the PC field, we are committed to providing our customers with optimal customized services to meet their needs of PC basic research.
Histopathological grading of PDAC serves as an important factor in prognostication, judged by criteria involving the presence of mucins, nuclear polymorphism, the number of mitoses, and the comparison of the tubular structure and solid growth. In addition to conventional histology, immunohistochemistry can be used to diagnose PDAC and distinguish it from other primary tumors in the event of metastasis.
We are committed to providing our clients with optimal and personalized services to support PC preclinical research projects. Here, we focus on PC cells and offer a series of PC cell research services. With experienced teams of scientists, researchers, and technicians, we provide fast turnaround and high-quality services at competitive prices for worldwide customers.
-PC cell line establishment and characterization
-PC cell analysis and evaluation
-PC cell metabolism research
CSCs are rare quiescent cells with the ability to self-renew through asymmetric/symmetrical cell division and to differentiate into various cell lines in cancer. More and more evidence supports that CSCs play an important role in cancer recurrence, metastasis, and are even responsible for drug resistance. Therefore, CSCs are potential targets for PC therapeutic strategies, and efforts are being made to eliminate CSCs.
-Pancreatic CSC isolation and characterization
-Induction of PC cells to pancreatic CSCs
-Detection and identification of pancreatic CSCs
As the major non-neoplastic component of the pancreatic tumor microenvironment (TME), CAFs not only promote the formation of the desmoplastic stroma by secreting extracellular matrix proteins but also regulate cancer progression by influencing cytokines/chemokine production. In addition, CAFs have also been reported to play an integral role in treatment resistance, including immunosuppression and chemoresistance. All these factors make CAFs potential therapeutic targets for treating PC.
Thanks to next-generation sequencing (NGS) technology and our established large-scale sequencing platforms, we can design and plan experimental protocols according to the specific needs of our clients and provide appropriate solutions for PC gene/ molecule exploration.
The investigation of potential biomarkers to assist in the screening, diagnosis, and treatment of PC has been an area of intensive research. We are able to help our clients with further research on the potential PC biomarkers and help them discover and identify new PC biomarkers. Our platform involves expertise across a wide range of disciplines, and our biomarker discovery and analysis services are refined down to every step of the process and overcome your internal data and analytical challenges.
PDAC tissue has been shown to possess a unique intratumoral bacterial profile with higher bacterial abundance compared to normal pancreatic samples. In addition to dysregulation of intra-tumor ecological dysregulation, differences in both intestinal and oral flora have been reported between PDAC patients and healthy individuals.
In order to further explore the mechanism of PC occurrence, development, invasion, and metastasis, and to promote the research of new therapeutic targets, it is necessary to establish a suitable preclinical model of PC. As a result, there is a growing need for preclinical models that can accurately simulate a patient's TME. We have years of experience in constructing tumor models for PC and can meet the specific requirements of our global customers.
Advantages of our services
- Extensive expertise in the field of PC basic research
- The excellent project management team
- Customized service to customer satisfaction
- Best after-sale service
Feel free to contact us with your inquiries about our PC basic research services.